Squamous cell carcinoma in situ

Managing Skin Cancer

Volumn , Issue , 2010, Pages 51-59

  Stockfleth, E ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84890004929     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-3-540-79347-2_4     Document Type: Chapter

References (64)

1. Ackerman AB (2003) Solar keratosis is squamous cell carcinoma. Arch Dermatol 139:1216-1217
2. Heaphy MR Jr, Ackerman AB (2000) The nature of solar keratosis: a critical review in historical perspective. J Am Acad Dermatol 43:138-150
3. Memon AA, Tomenson JA, Bothwell J, Friedmann PS (2000) Prevalence of solar damage and actinic keratosis in a Merseyside population. Br J Dermatol 142:1154-1159
4. Salasche SJ (2000) Epidemiology of actinic keratoses and squamous cell carcinoma. J Am Acad Dermatol 42:4-7
5. Frost C, Williams G, Green A (2000) High incidence and regression rates of solar keratoses in a queensland community. J Invest Dermatol 115:273-277
6. Stockfleth E, Ulrich C, Meyer T, Christophers E (2002a) Epithelial malignancies in organ transplant patients: clinical presentation and new methods of treatment. Recent Results Cancer Res 160:251-258
7. Ulrich C, Christophers E, Sterry W, Meyer T, Stockfleth E (2002) Skin diseases in organ transplant patients. Hautarzt 53:524-533
8. Brash DE, Ziegler A, Jonason AS, Simon JA, Kunala S, Leffell DJ (1996) Sunlight and sunburn in human skin cancer: p53, apoptosis, and tumor protection. J Invest Dermatol Symp Proc 1:136-142
9. Chuang T Y, Heinrich LA, Schultz MD, Reizner GT, Kumm RC, Cripps DJ (1992) PUVA and skin cancer. A historical cohort study on 492 patients. J Am Acad Dermatol 26 (2 Pt 1):173-177
10. Jackson S, Storey A (2000) E6 proteins from diverse cutaneous HPV types inhibit apoptosis in response to UV damage. Oncogene 19:592-598
11. Jackson S, Harwood C, Thomas M, Banks L, Storey A (2000) Role of Bak in UV-induced apoptosis in skin cancer and abrogation by HPV E6 proteins. Genes Dev 14:3065-3073
12. Hazard K, Karlsson A, Andersson K, Ekberg H, Dillner J, Forslund O (2007) Cutaneous human papillomaviruses persist on healthy skin. J Invest Dermatol 127(1):116-119
13. Nindl I, Gottschling M, Stockfleth E (2007) Human papillomaviruses and non-melanoma skin cancer: basic virology and clinical manifestations. Dis Markers 23(4):247-259
14. Braakhuis B J M, Tabor MP, Kummer JA, Leemans CR, Brakenhoff RH (2003) A genetic explanation of Slaughter's concept of field cancerization. Evidence and clinical implications. Cancer Res 63:1727-1730
15. Berhane T, Halliday GM, Cooke B, Barnetson R S C (2002) Inflammation is associated with progression of actinic keratoses to squamous cell carcinomas in humans. Br J Dermatol 146:810-815
16. Ulrich M, Maltusch A, Röwert-Huber J, González S, Sterry W, Stockfleth E, Astner S (2007) Actinic keratoses: non-invasive diagnosis for field cancerisation. Br J Dermatol 156(Suppl 3):13-17
17. Röwert-Huber J, Patel MJ, Forschner T, Ulrich C, Eberle J, Kerl H, Sterry W, Stockfleth E (2007) Actinic keratosis is an early in situ squamous cell carcinoma: a proposal for reclassification. Br J Dermatol 156(Suppl 3):8-12
18. Emmett AJ, Broadbent GD (1987) Shave excision of superficial solar skin lesions. Plast Reconstr Surg 80:47-54
19. Dinehart SM (2000) The treatment of actinic keratoses. J Am Acad Dermatol 42:25-28
20. Drake LA, Ceiley R, Cornelison RL, Dobes WL, Dorner W, Goltz W, Graham G, Lewis CW, Salasche SJ, Chanco Turner ML, Lewery BJ (1995) Guidelines of care for actinic keratoses. J Am Acad Dermatol 32:95-98
21. Zouboulis Ch C (1999) Principles of cutaneous cryosurgery: an update. Dermatology 198:111-117
22. Chiarello SE (2000) Cryopeeling (extensive cryosurgery) for treatment of actinic keratoses: An update and comparison. Dermatol Surg 26:728-732
23. ® to cryotherapy in actinic keratoses. J Eur Acad Dermatol Venereol 14:235
24. Lubritz RR, Smolewski SA (1982) Cryosurgery cure rate of actinic keratoses. J Am Acad Dermatol 7:631-632
25. Witheiler DD, Lawrence N, Cox SE, Cruz C, Cockerell CJ, Freeman RG (1997) Long-term efficacy and safety of Jessner's solution and 35% trichloroacetic acid vs 5% fluorouracil in the treatment of widespread facial actinic keratoses. Dermatol Surg 23:191-196
26. Lawrence N (2000) New and emerging treatments for photoaging. Dermatol Clin 18:99-112
27. Otley CC, Roenigk RK (1996) Medium-depth chemical peeling. Semin Cutan Med Surg 15:145-154
28. Stone PA (1998) The use of modified phenol for chemical face peeling. Clin Plast Surg 25:21-44
29. Iyer S, Friedli A, Bowes L, Kricorian G, Fitzpatrick RE (2004) Full face laser resurfacing: therapy and prophylaxis for actinic keratoses and non-melanoma skin cancer. Lasers Surg Med 34:114-119
30. Wollina U, Konrad H, Karamfilov T (2001) Treatment of common warts and actinic keratoses by Er:YAG laser. J Cutan Laser Ther 3:63-66
31. Yu TC, Rahman Z, Ross BS (2003) Actinic keratoses - surgical and physical therapeutic modalities. Cutis 71:381-384
32. Fulton JE, Rahimi AD, Helton P, Dahlberg K, Kelly AG (1999) Disappointing results following resurfacing of facial skin with CO2 lasers for prophylaxis of keratoses and cancers. Dermatol Surg 25:729-732
33. Szeimies RM, Karrer S, Radakovic-Fijan S, Tanew A, Calzavara-Pinton PG, Zane C, Sidoroff A, Hempel M, Ulrich J, Proebstle T, Meffert H, Mulder M, Salomon D, Dittmar HC, Bauer JW, Kernland K, Braathen L (2002) Photodynamic therapy using topical methyl 5-aminolevulinate compared with cryotherapy for actinic keratosis: a prospective, randomized study. J Am Acad Dermatol 47:258-262
34. Morton CA, Brown SB, Collins S, Ibbotson S, Jenkinson H, Kurwa H, Langmack K, McKenna K, Moseley H, Pearse AD, Stringer M, Taylor DK, Wong G, Rhodes LE (2002) Guidelines for topical photodynamic therapy: report of a workshop of the British Photodermatology Group. Br J Dermatol 146:552-567
35. Pariser DM, Lowe NJ, Stewart DM, Jarrat MT, Lucky AW, Pariser RJ, Yamauchi PS (2003) Photodynamic therapy with topical methyl aminolevulinate for actinic keratosis: results of a prospective randomized multicenter trial. J Am Acad Dermatol 48:227-232
36. Freeman M, Vinciullo C, Francis D, Spelman L, Nguyen R, Fergin P, Thai KE, Murrell D, Weightman W, Anderson C, Reid C, Watson A, Foley P (2003) A comparison of photodynamic therapy using topical methyl aminolevulinate (Metvix) with single cycle cryotherapy in patients with actinic keratosis: a prospective, randomized study. J Dermatolog Treat 14:99-106
37. Hemmi H, Kaisho T, Takeuchi O, Sato S, Sanjo H, Hoshino K, Horiuchi T, Tomizawa H, Takeda K, Akira S (2002) Small antiviral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol 3:196-200
38. Miller RL, Gerster JF, Owens ML, Slade HB, Tomai MA (1999) Imiquimod applied topically: a novel immune response modifier and new class of drug. Int J Immunop harmacol 21:1-14
39. Stockfleth E, Meyer T, Benninghoff B, Salasche S, Papadopoulos L, Ulrich C, Christophers E (2002b) A randomized, double-blind, vehicle-controlled study to assess 5% imiquimod cream for the treatment of multiple actinic keratoses. Arch Dermatol 138:1498-1502
40. Stockfleth E, Christophers E, Benninghoff B, Sterry W (2004b) Low incidence of new actinic keratoses after topical 5% imiquimod cream treatment: a long-term follow-up study. Arch Dermatol 140:1542
41. Lebwohl M, Dinehart S, Whiting D, Lee PK, Tawfik N, Jorizzo J, Lee JH, Fox TL (2004) Imiquimod 5% cream for the treatment of actinic keratosis: results from two phase III, randomized, double-blind, parallel group, vehicle-controlled trials. J Am Acad Dermatol 50(5):714-721
42. Gupta AK (2002) The management of actinic keratoses in the United States with topical fluorouracil: a pharmacoeconomic evaluation. Cutis 70:30-36
43. Lawrence N, Cox SE, Cockerell CJ, Freeman RG, Cruz PD Jr (1995) A comparison of the efficacy and safety of Jessner's solution and 35% trichloroacetic vs 5% fluorouracil in the treatment of widespread facial actinic keratoses. Arch Dermatol 131:176-181
44. Levy S, Furst K, Chern W (2001) A comparison of the skin permeation of three topical 0.5% fluorouracil formulations with that of a 5% formulation. Clin Ther 23:901-907
45. Jorizzo J, Stewart D, Bucko A, Davis A, Davis SA, Espy P, Hino P, Rodriguez D, Savin R, Stough D, Furst K, Connolly M, Levy S (2002) Randomized trial evaluating a new 0.5% fluorouracil formulation demonstrates efficacy after 1-, 2-, or 4-week treatment in patients with actinic keratosis. Cutis 10:335-339
46. Loven K, Stein L, Furst K, Levy S (2002) Evaluation of the efficacy and tolerability of 0.5% fluorouracil cream and 5% fluorouracil cream applied to each side of the face in patients with actinic keratosis. Clin Ther 24:990-1000
47. Sachsenberg-Studer EM (1999) Tolerance of topical retinaldehyde in humans. Dermatology 199:S61-63
48. Sorg O, Tran C, Saurat JH (2001) Cutaneous vitamins A and E in the context of ultraviolet-or chemically-induced oxidative stress. Skin Pharmacol Appl Skin Physiol 14:363-372
49. Moriarty M, Dunn J, Darragh A, Lambe R, Brick I (1982) Etretinate in treatment of actinic keratosis. A double-blind crossover study. Lancet 13:364-365
50. Di Giovanna JJ (2001) Retinoid chemoprevention in patients at high risk for skin cancer. Med Pediatr Oncol 36:564-567
51. McNamara IR, Muir J, Galbraith AJ (2002) Acitretin for prophylaxis of cutaneous malignancies after cardiac transplantation. J Heart Lung Transplant 21:1201-1205
52. Jung YJ, Isaacs JS, Lee S, Trepel J, Neckers L (2003) IL-1β-mediated up-regulation of HIF-1α via an NFκB/COX-2 pathway identifies HIF-1 as a critical link between inflammation and oncogenesis. FASEB J 17:2115-2117
53. Rivers JK, Arlette J, Shear N, Guenther L, Carey W, Poulin Y (2002) Topical treatment of actinic keratoses with 3.0% diclofenac in 2, 5% hyaluronan gel. Br J Dermatol 146:94-100
54. Gebauer K, Brown P, Varigos G (2003) Topical diclofenac in hyaluronan gel for the treatment of solar keratoses. Australas J Dermatol 44:40-45
55. Wolf JE Jr, Taylor JR, Tschen E, Kang S (2001) Topical 3, 0% diclofenac in 2, 5% hyaluronan gel in the treatment of actinic keratoses. Int J Dermatol 40:709-713
56. Armstrong BK, Kricker A (2001) The epidemiology of UV induced skin cancer. J Photochem Photobiol B 63:8-18
57. Thompson SC, Jolley D, Marks R (1993) Reduction of solar keratoses by regular sunscreen use. N Engl J Med 329:1147-1151
58. Ulrich C, Jürgensen JS, Degen A, Hackethal M, Ulrich M, Patel MJ, Eberle J, Terhorst D, Sterry W, Stockfleth E (2009) Prevention of non-melanoma skin cancer in organ transplant patients by regular use of a sunscreen: a 24 months, prospective, case-control study.; Br J Dermatol 161(Suppl 3):78-84
59. Bowen JT (1912) Precancerous dermatoses: a study of two cases of chronic atypical epithelial proliferation. J Cutan Dis 30:241-255
60. Cox NH, Eedy DJ, Morton CA (1999) Guidelines for management of Bowen's disease. Br J Dermatol 141:633-641
61. Lycka B A S (1989) Bowen's disease and internal malignancy. A meta analysis. Int J Dermatol 28:531-533
62. Thestrup-Pedersen K, Ravnborg L, Reymann F (1988) Morbus Bowen. Acta Derm Venereol (Stockh) 68:236-239
63. Moreno G, Chia A L K, Lim, Shumack S (2007) Therapeutic options for Bowen's disease. Australas J Dermatol 48:1-10
64. Rosen T, Harting M, Gibson M (2007) Treatment of Bowen's disease with topical 5% imiquimod cream. Retrospective study. Dermatol Surg 33:427-432